In a small trial, patients with the highest tertile of IL-6 experienced significantly faster progression of diabetic kidney disease.
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
The study evaluated finerenone in addition to standard of care in patients with chronic kidney disease and type 2 diabetes.
Non-linear renal function decline frequently occurs in patients with type 2 diabetes and is associated with faster progression to end-stage kidney disease.
The prevalence of hypertension and albuminuria in pediatric patients with type 2 diabetes varies by race.
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
Urinary albumin-to-creatinine ratio values are often used to guide treatment decisions as albuminuria is known to be a strong predictor of cardiovascular and renal events.
A move toward combination therapies is inevitable in the new paradigm for diabetic kidney disease management, according to the authors of an editorial.